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Abstract  
A urinary tract infection (UTI) is defined as a temporary or permanent breach in host defense 
mechanisms that allows microbes to adhere, multiply, and persist within the urinary tract.  
Development of a UTI is multi-factorial with bacterial number and virulence and the health 
status of the patient (normal urogenital tract anatomy and physiology and systemic 
immunocompetence) playing important roles in determining the outcome.  A UTI can involve a 
single site, such as the renal pelvis, ureter, bladder, urethra, prostate or vagina, or can include 
multiple sites.  Infection of any portion of the urinary tract may increase the likelihood of 
infection in other locations.   
Diagnosis of a UTI incorporates findings from the history, physical examination, complete 
urinalysis, and urine culture.  Proper classification and localization of the UTI are important 
when formulating a treatment regime as well as evaluating treatment success and failure.  Most 
UTI can be successfully managed with appropriate antibiotic treatment; however, bacterial 
resistance and compromised host defense mechanisms can result in persistent or recurrent 
infections.  In patients with recurrent UTI, identification of underlying predisposing conditions 
will often improve treatment success.  In patients where underlying causes cannot be identified 
or treated, therapies designed to prevent recurrent UTI may be employed.   
Proanthrocyanidins found in cranberry juice inhibit E. coli attachment to human uroepithelial 
cells, impairing bacterial adherence and colonization.  These characteristics have encouraged 
widespread usage of cranberry extract as a prevention strategy for woman predisposed to urinary 
tract infections.  E. coli is a common cause of canine urinary tract infection. Current treatment 
emphasizes eradication of established infection rather than infection prevention, but increased 
antibiotic resistance necessitates strategies to prevent infection. We hypothesized that purified 
cranberry extract (CE) inhibits bacterial adhesion to canine uroepithelial cells.  The results of our 
study show that CE supplementation can reduce adhesion of uropathogenic E. coli to canine 
uroepithelium and suggests one mechanism by which CE might improve urinary tract health. 
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Chapter 1 - Review of Urinary Tract Infections in Small Animals 
 Etiology and Pathogenesis  
 Incidence and prevalence 
Bacterial urinary tract infection (UTI) is common; approximately 5-27% of dogs will experience 
infections of the urinary tract at some point during their lifetime.
1-3
  Female dogs are more 
commonly affected than are males.  A large retrospective study of canine urine cultures reported 
bacterial growth in 37% of submissions from female dogs and 29% of submissions from male 
dogs.
4
 In contrast to dogs, bacterial UTI are relatively rare in cats.  In young, otherwise healthy 
cats with signs of lower urinary tract inflammation, bacterial UTI is rare (<2%).
5, 6
  Incidence of 
bacterial UTI in cats increases with age and occurs more often in cats older than 10 years.
7-9 
 
 Asymptomatic bacteriuria 
Not all species of bacteria will induce clinical signs or cause disease.  In some cases the bacteria 
present in animals with an asymptomatic bacteriuria may provide protection against colonization 
of the urinary tract with more pathogenic strains of bacteria (Table 1.1).
10
  This is important 
since some patients that are treated for an asymptomatic bacteriuria may subsequently develop 
infections of the urinary tract with pathogenic strains of bacteria.
11
  Asymptomatic bacteriuria 
associated with UTI most often occur secondary to systemic disease or immunocompromise.  
Chapter two discusses treatment considerations for asymptomatic bacteriuria. 
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Table 1.1 Commensal Bacterial Genera in the Urogenital Tract of Dogs 
 
Genus Distal Urethra of 
Males 
Prepuce Vagina 
Acinetobacter  + + 
Bacteroides   + 
Bacillus  + + 
Citrobacter   + 
Corynebacterium + + + 
Enterococcus   + 
Enterobacter   + 
Escherichia + + + 
Flavobacterium + + + 
Haemophilus + + + 
Klebsiella + + + 
Micrococcus   + 
Moraxella  + + 
Mycoplasma + + + 
Neisseria   + 
Pasteurella  + + 
Proteus  + + 
Pseudomonas   + 
Staphylococcus + + + 
Streptococcus + + + 
Ureaplasma + + + 
 
From Barsanti JA:  Genitourinary infections.  In Greene CE, editor: Infectious diseases of the 
dog and cat, ed 3, St Louis, 2006, Saunders, pp 935-961. 
 
 Inflammation versus infection 
Evidence of inflammation (e.g., pyuria) in the urine sediment is not synonymous with a UTI.  
There are several nonbacterial diseases that can result in urinary tract inflammation and 
subsequent clinical signs may be similar to those of a UTI (e.g., dysuria, pollakiuria, hematuria).  
Examples include sterile urocystoliths, urethral obstruction, lower urinary tract neoplasia, lower 
urinary tract trauma, as well as sterile polypoid, irritant, and idiopathic cystitis. Bacteriuria with 
inflammation on sediment exam are diagnostic for a UTI from cystocentesis samples, however in 
some cases urine culture may be necessary for a diagnosis. 
3 
 
 Microbial isolates 
The most common isolate from the canine urine is Escherichia coli which accounts for one-third 
to half of all positive urine cultures.
4,12
  The next major group of uropathogens includes Gram-
positive cocci, such as Staphylococcus, Streptococcus, and Enterococcus.  Remaining 
uropathogens include Proteus, Klebsiella, Pasteurella, Mycoplasma, Enterobacter and 
Pseudomonas.
4, 12
  These 10 genera accounted for 95% and 97% of all urinary isolates in male 
and female dogs, respectively.
4
  A study evaluating prevalence in an Australian cat population 
found E. coli to be the most common pathogen (37%), followed by Enterococcus (27%) and 
Staphylococcus (20%).
13, 14  
A retrospective analysis of feline urine cultures submitted to a 
teaching hospital also found E. coli  to be the most common pathogen (47%), followed by 
Staphylococcus (18%), Streptococcus (13%) and Klebsiella (4%).
14
  In both dogs and cats with 
bacterial UTI, 75% of the time there is a single pathogen; in 20% of cases there are two 
pathogens and < 5% of the time there are three species.
12
  Multiple organism infections are more 
commonly observed in female dogs.
4
  Infections with bacteria such as Pseudomonas are more 
commonly associated with opportunistic infection secondary to immunocompromise or 
alterations in host defenses.
15
  
 Antimicrobial resistance 
Intrinsic and acquired forms of antimicrobial resistance exist.  Intrinsic resistance mechanisms 
are genetic based bacterial properties.
16
  For example, penicillinase producing strains of 
Staphylococcus have intrinsic resistance to penicillins.  Although there are limited ways to 
address intrinsic resistance, veterinarians play a large role in acquired forms of resistance since 
bacterial populations respond to selection pressures brought about by use of antimicrobial agents.  
With increasing use of antimicrobials there is increased risk of resistance.  This not only has the 
potential to affect our veterinary patients, but also the people that live with them.
17, 18
  
Acquired resistance is created by alterations in bacterial DNA.  Bacteria have numerous 
mechanisms for exchanging genetic material which can contribute to acquired antimicrobial 
resistance.  The genetic information in most bacteria is in the form of plasmids, which are small, 
circular stands of DNA.  Plasmids do not carry genes responsible for essential metabolic 
function, but can carry genes for virulence and resistance.  Transposons are another type of 
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mobile genetic element which can contribute to resistance by excising themselves from the donor 
chromosome and inserting into recipient chromosomes or plasmids.  Plasmids and transposons 
can be passed between bacterial strains and across species within a bacterial family by 
conjugation.
1
  Finally, chromosomal mutations are also possible which can produce resistant 
modifications in the antibiotic target. 
 Routes of infection 
Most UTI are associated with bacterial pathogens from the gastrointestinal tract or skin 
surrounding the vulva and prepuce that ascend via the urethra to the urinary bladder.  Once 
bacteria gains entrance to the urinary tract, they adhere and colonize the urothelial surface.  The 
ability to establish these colonies depends on the number and virulence of the ascending 
microbes versus the competence of the host defense mechanisms. 
Ascension of bacteria from the lower urinary tract is the primary route of infection of the upper 
urinary tract (versus hematogenous or direct extension from surrounding tissues).  The most 
common site of infection in the upper urinary tract is the renal pelvis but invasion into the renal 
parenchyma is possible.
19
  Ascension from the lower urinary tract may occur in association with 
vesicoureteral reflux and/or an obstructive uropathy.  Obstruction to urine flow can decrease 
renal medullary blood flow via increased back pressure and cause decreased delivery of 
antibody, complement, and white blood cells to the medulla, increasing the risk of bacterial 
colonization of the renal pelvis.  A small percentage of UTI are caused by bacteria that have 
entered the tract through a hematogenous route.  While the development of a UTI via the 
hematogenous route is uncommon, it occurs most frequently in the kidney.  In cases of 
bacteremia, the high renal blood flow and the extensive filtration surface within the glomeruli 
expose the kidney to bacteria. 
 Normal host defense mechanisms 
Host defense mechanisms are comprised of a combination of anatomic and physiologic factors 
that have a major role in preventing a UTI.  Beyond prevention, the status of host defense 
mechanisms is one of the most important determinants of the outcome of a UTI.  Appropriate 
antibiotic treatment will, at best, sterilize the urinary tract during the time of administration but it 
is the host defense mechanisms that prevent recurrent UTI (reinfections) after antibiotic 
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withdrawal.  Diagnosis of defense breaches can help identify possible reasons for treatment 
failures as well as patients at risk of acquiring a UTI. 
 Normal urine storage and voiding 
Production of a normal amount of urine with frequent and complete voiding helps reduce the 
number of bacteria ascending through the urethra and adhering to the bladder uroepithelium.  
Research in rats infected with E. coli identified two phases of bacterial clearance during voiding.  
The primary phase occurred 0-4 hours after the introduction of bacteria and the secondary phase 
occurred 4-24 hours after the introduction of bacteria.  Ninety nine percent of bacteria are cleared 
from the urinary bladder via micturition within 4 hours of introduction.
20
 
Any condition that decreases the frequency of voiding can predispose a patient to a UTI by 
providing more time for bacterial adherence.  For example, dogs with upper motor neuron 
lesions often have urine retention associated with increased outflow resistance and subsequent 
bladder atony; incomplete bladder emptying in these patients increases the potential for 
infection.  Similarly, retention of urine associated with decreased detrusor contractility (e.g., 
lower motor neuron lesions and dysautonomia) is also associated with decreased bacterial 
washout and increased predisposition to UTI.
21
  From a clinical management perspective, 
prolonged time between voiding opportunities (e.g., owner work schedules) may also predispose 
or make it more difficult to eradicate a UTI. 
Although diuresis and increased frequency of voiding in humans has been found to decrease the 
bacterial colony count in patients diagnosed with a UTI, reduced frequency of voiding in the face 
of dilute urine (e.g., at night when the patient is asleep) can result in increased urine bacterial 
counts.
22
  Dilute urine with low concentrations of urea may predispose dogs and cats to the 
development of UTI because bacteria have increased ability to grow in these conditions 
compared with the harsher environment of highly concentrated urine.
23, 24
  The importance of 
bladder washout versus antibacterial properties of concentrated urine has not been investigated in 
dogs; however it is likely both have clinical significance.  In my opinion, in dogs and cats with 
decreased urine concentrating ability urine culture should be part of longitudinal monitoring 
recommendations. 
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 Anatomic structures 
There are several anatomic features of the urethra, ureters and prostate that help prevent infection 
and/or ascension of bacteria.  First, the high pressure zone of the urethral sphincter impedes 
migration of bacteria.  In contrast to urine retention, urethral sphincter mechanism incompetence 
(USMI) and lower urethral closure pressures may also compromise host defenses by allowing a 
greater number of bacteria to more easily ascend through the urethra to the bladder. 
Secondly, ureteral peristalsis inhibits further ascension of bacteria above the level of the bladder.  
Finally, in male dogs, prostatic secretions that contain zinc and are bacteriostatic, along with 
increased urethral length, are important defense mechanisms that make UTI relatively rare.
25,26
  
Congenital and/or acquired anatomic abnormalities of the urogenital system frequently 
predispose patients to UTI.  Vaginal strictures resulting in urine pooling or urine retention can 
increase the time for bacterial adherence/colonization of the lower urinary tract.  Ectopic ureters 
lack the normal vesicoureteral valve; therefore bacteria from the lower tract may more easily 
ascend to the upper tract.  A recessed vulva and excessive perivulvar skin folds often result in a 
localized moist bacterial dermatitis and increased bacterial ascension through the urethra. 
 Mucosal defense barriers 
The uroepithelium lines the lumen of the urinary tract from the renal pelvis to the urethra and 
prevents the passage of water, ions, solutes and macromolecules from the plasma and 
interstitium into the urinary tract lumen.
27
  A healthy uroepithelium also prevents adherence of 
bacteria.  For example in a small study, perineal urethrostomy surgery did not increase the risk of 
UTI in cats with a healthy uroepithelium.  However persistent uroepithelial inflammation, 
combined with surgical alteration in anatomic and functional barriers to ascending UTI is 
associated with a higher incidence of UTI in cats.
28
 
Within the bladder, the uroepithelium is composed of three layers: basal cells, intermediate 
polygonal cells, and the most superficial umbrella cells.  The umbrella cells form a single layer, 
are separated by cellular tight junctions, and can alter their shape depending on the degree of 
bladder distention.
27
  The apical membranes of the umbrella cells are composed of plaques and 
hinges that facilitate stretching and bladder filling.  The plaques are made up of inner and outer 
leaflets that form an asymmetric unit membrane (AUM).  The AUM is composed of 
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transmembrane proteins called uroplakins.  One of the main functions of these uroplakins is to 
form a barrier to solute and water flow across the apical membrane.
27
  If ascending bacteria bind 
to these uroplakins, uroepithelial apoptosis can be initiated resulting in washout of the infected 
cells. 
In some cases, the adherence of bacteria to the uroepithelium can lead to the cellular 
internalization of bacteria.  Bacteria within uroepithelial cells are protected from the host’s 
immune response and have the ability to serve as a reservoir for recurrent infections.   
Glycosaminoglycans (GAG) and proteoglycans are produced by umbrella cells and are part of 
the bladder surface mucus layer.  Glycosaminoglycans are hydrophilic and bind water to the 
apical membrane of the transitional cell.  This water layer decreases the ability of bacteria and 
crystals to adhere to the uroepithelium and contributes to the impermeability of the bladder 
wall.
29
  With chemical (e.g., cyclophosphamide administration) or mechanical damage (e.g., 
presence of uroliths, neoplasia, or over-insertion of a urethral catheter), the GAG layer can be 
disrupted resulting in increased adherence of bacteria to the bladder mucosa.
30
  Disruption of the 
GAG layer also increases the permeability of the bladder wall allowing irritating substances to 
pass through the uroepithelium and cause submucosal inflammation.
31
 
Secretory IgA (sIgA) is the primary immunoglobulin in mucous secretions from the urogenital 
tract.  It differs from serum IgA by being bound to a secretory protein component.
32
  The 
secretory component complexes with polymeric IgA released by the plasma cells in the lamina 
propria of mucous membranes allowing transport of IgA across the epithelial barrier and into the 
lumen.
33
  Widening of the interstitial space between uroepithelial cells associated with 
inflammation may facilitate secretion of IgA.
34
  Secretory IgA inhibits attachment of E. coli to 
human uroepithelial cells by binding to bacteria that enter the mucous layer of the 
uroepithelium.
35
  Once a bacterium is coated with this secretory antibody, its ability to adhere to 
the uroepithelium is compromised.
34
   
Another mucosal defense mechanism involves normal flora occupying distal uroepithelium 
receptor sites.  Normal flora of the urogenital tract compete with potential pathogens for 
nutrients and epithelial receptor sites.  Bacteriocins are natural antibiotics produced by almost all 
bacteria.
36
  Normal flora may produce bacteriocins that are inhibitory and/or bactericidal to 
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potential pathogens.
37
  The antibiotic properties of these bacteriocins have a relatively narrow 
spectrum and are only toxic to closely related strains.  Colicin is the most commonly evaluated 
bacteriocin in E. coli infections.
36
  Urinary catheters coated with a colicin-producing strain of E. 
coli have been used to prevent UTI in people.
38
  Currently there are no studies evaluating use of 
these catheters in veterinary medicine. 
 Antimicrobial properties of urine 
The antibacterial properties of urine contribute to host defenses via bacteriostatic and possibly 
bactericidal effects depending on urine composition.  Potential mechanisms for these 
antibacterial properties include low pH, high concentrations of urea and weak organic acids, and 
high urine specific gravity (USG).  In children with recurrent UTI, inhibition of bacterial growth 
was correlated with increasing urine specific gravity (USG).
39
  Urine osmolality and USG have 
been proposed as a reason why healthy cats have relatively few UTI.  However, since high USG 
does not always correlate with antimicrobial activity, there are likely other factors or substances 
in concentrated urine that inhibit bacterial growth.
23, 24
  Maintaining a patient’s urine pH between 
5.0-6.5 helps inhibit the growth of bacteria in people.
40
  However, a study looking at antibacterial 
properties of feline urine found no correlation with pH and inhibition of UTI.
23
  In acidic urine in 
canine patients, the inhibition of bacterial growth may be more pronounced for bacteria like 
Proteus, that tend to grow better in an alkaline environment. 
 Localization 
Urinary tract infections most commonly colonize the uroepithelial cells of the bladder but 
involvement of the kidneys, prostate, and uterus is also possible.  If the male dog is intact, 
colonization of the prostate should be expected.  The location of the UTI can be determined in 
most cases based on the history, physical examination findings, laboratory parameters and 
imaging results (Table 1.2).   
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Table 1.2 Localization of Urinary Tract Infections 
 
   
Site of 
Infection 
Compatible 
History 
Potential Physical 
Examination Findings Laboratory Findings 
Diagnostic Imaging 
Findings 
Lower 
urinary tract-
uncomplicated 
Dysuria, 
pollakiuria, 
periuria, hematuria, 
cloudy urine with 
abnormal odor, 
usually no systemic 
signs 
Small, painful, thickened 
bladder 
CBC: WNL Urinalysis: 
Pyuria, hematuria, 
proteinuria, bacteriuria 
Urine culture:  Significant 
bacteriuria † Often  unremarkable 
Lower 
urinary tract-
complicated 
Dysuria, 
pollakiuria, 
periuria, hematuria, 
cloudy urine with 
abnormal odor, 
usually no systemic 
signs 
Small, painful, thickened 
bladder, palpable masses in 
urethra or bladder, flaccid 
bladder wall, large residual 
volume, +/- palpation of 
uroliths 
CBC: WNL Urinalysis: 
Pyuria, hematuria, 
proteinuria, bacteriuria 
CHEM: consistent with 
underlying endocrinopathies 
Urine culture:  Significant 
bacteriuria  † 
Possible changes in 
renal size and shape 
(with CKD), urinary 
tract masses, +/- 
uroliths, +/- thickening 
of bladder wall, +/-
changes consistent with 
endocrine disease 
Acute 
pyelonephritis 
+/-polyuria, 
polydipsia, +/- 
possible lethargy, 
depression, 
anorexia, +/- renal 
failure 
Fever, depression, 
lethargy, lumbar pain that 
would not be expected with 
a simple cystitis. 
CBC:  +/-
Leukocytosis/inflammatory 
leukogram Urinalysis: 
pyuria, hematuria, 
proteinuria, bacteriuria, 
WBC or granular casts, 
impaired urine concentration, 
+/- azotemia 
Renomegaly, +/- 
abnormal kidney shape, 
+/- nephroliths, 
ureteroliths, +/- dilated 
renal pelvis, dilated 
pelvic diverticulae, +/- 
evidence of outflow 
obstruction. 
 
Acute 
prostatitis 
Urethral discharge 
independent of 
micturition, +/- 
reluctance to 
urinate or defecate 
Fever, depression, 
lethargy, painful prostate 
or abdomen, rectal exam 
showing asymmetric or 
enlarged prostate 
CBC:  +/-
Leukocytosis/inflammatory 
leukogram Urinalysis: 
pyuria, hematuria, 
proteinuria, bacteriuria 
+/- indistinct prostate 
borders, +/- 
prostatomegaly, +/- 
prostatic cysts 
Chronic 
pyelonephritis 
+/- polyuria, 
polydipsia, +/- 
signs of systemic 
infections, +/- renal 
failure 
+/-abdominal pain, kidneys 
normal or decreased in size 
CBC:  +/-
Leukocytosis/inflammatory 
leukogram Urinalysis: 
pyuria, hematuria, 
proteinuria, bacteriuria, 
WBC or granular casts, 
impaired concentration, +/- 
azotemia or worsening 
azotemia 
+/- abnormal kidney 
shape, +/- nephroliths, 
ureteroliths, +/- dilated 
renal pelves, dilated 
pelvic diverticulae, +/- 
evidence of outflow 
obstruction 
Chronic 
prostatitis 
recurrent UTI, 
urethral discharge 
independent of 
urination, +/- 
dysuria 
Often no detectable 
abnormalities, +/- 
prostatomegaly or 
asymmetric prostate 
CBC: WNL, Urinalysis: 
pyuria, hematuria, 
proteinuria, bacteriuria 
+/- prostatomegaly, +/- 
prostatic cysts, +/- 
prostatic mineralization  
† Significant bacteriuria defined based on collection method and bacterial quantification (see 
Table 2.1)  Adapted from Pressler B, Bartges JW:  Urinary Tract Infections.  In Ettinger, editor: 
Textbook of Veterinary Internal Medicine, ed 7, St Louis, 2010, Saunders, pp 2040. 
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 Complicating factors 
 Complicated versus uncomplicated UTI 
Uncomplicated UTI occur in patients where no underlying structural, neurologic, or functional 
abnormalities exist.  A UTI becomes complicated when host defense mechanisms are 
compromised either due to structural abnormalities altering urothelium (e.g., cystolithiasis), 
anatomic abnormalities (e.g., USMI) changes to the urine such as glucosuria, decreased urine 
osmolality, or decreased neutrophilic chemotaxis (e.g., diabetes mellitus) or suppression of the 
inflammatory or immune response secondary to hypercortisolemia (e.g., hyperadrenocorticism).  
In addition, UTIs are often considered complicated if they occur in cats, male dogs, and intact 
female dogs, or if they involve the kidneys or prostate.
24,41
  The distinction between 
uncomplicated and complicated UTI is helpful for determining prognosis, risk for recurrence, 
duration of treatment, and follow up recommendations for recheck evaluations. 
 Systemic disease 
Urinary tract infections are common in dogs and cats with systemic diseases that may 
compromise normal antimicrobial defenses.  In a retrospective study of 101 dogs with diabetes 
mellitus or hyperadrenocorticism or both, 42 (41.6%) had a UTI.
42
  Dogs receiving long-term 
glucocorticoids are also at risk with a reported incidence of 18-39%.
43, 44
  Similarly, systemic 
disease can predispose cats to UTI.  In retrospective studies evaluating known predisposing 
conditions in cats, positive urine cultures were found in 17-30 % of cats with CKD, 12-13% of 
cats with DM, and 12-22% of cats with hyperthyroidism.
41,45, 46  
In one of these studies 
decreasing USG was not associated with positive urine culture; however, pyuria and hematuria 
were associated with positive urine cultures.
45
  In addition, Persian breed, females, increasing 
age, and decreasing body weight were associated with positive cultures.
45
  Urinary tract 
infections that occur secondary to immunocompromising systemic disease may be clinically 
silent due to decreased white blood cell chemotaxis to the bladder and may be difficult to detect 
if a low USG is present. 
11 
 
 Conclusion 
In conclusion, bacterial UTI are common in female dogs and older cats with concurrent systemic 
disease.  Bacteria usually gain entrance to the urinary tract via ascension through the urethra.  
The ability of bacterial pathogens to adhere and colonize the uroepithelium is determined by the 
interplay of bacterial virulence factors and normal host defense mechanisms.  Understanding 
these factors should improve treatment and prevention of UTI.   
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Chapter 2 - Review of Urinary Tract Infections in Small Animals 
 Diagnosis, Treatment and Complications 
 Clinical findings 
 History 
Clinical signs associated with a urinary tract infection (UTI) depend on bacterial virulence, status 
of the host immune system, duration of the infection, and the site or sites of infection.  The most 
common clinical signs associated with lower UTI include pollakuria, stranguria, dysuria, 
hematuria and inappropriate urination or periuria.  If a UTI occurs secondary to a micturition 
disorder, such as an ectopic ureter, urethral sphincter mechanism incompetence (USMI), or urine 
retention, clinical signs associated with the primary condition may predominate.  Similarly, in 
dogs and cats with systemic disease and compromised host defense mechanisms, clinical signs 
associated with the underlying disease may predominate and the UTI may be relatively 
asymptomatic. 
 Physical exam 
Dogs with uncomplicated UTI often have unremarkable physical examination findings. 
Predisposing causes such as vulvar involution (Figure 2.1), severe perivulvular dermatitis, 
vaginal stenosis, cystic or urethral calculi, or urethral thickening may be identified in patients 
with complicated UTI.  Whenever possible, female dogs that present with a UTI should have a 
digital vaginal examination performed in order to identify an anatomical abnormality that may 
alter normal host defense mechanisms.  For example, palpation of a persistent paramesonephric 
remnant (Figure 2.2) may prompt further investigation for ectopic ureters and palpation of 
vaginal strictures may prompt further investigation for urine retention.  Rectal examination (male 
and female dogs and cats) may also identify abnormalities such as pelvic trauma, urethral stones, 
or urethral thickening associated with neoplasia or granulomatous urethritis.  These findings can 
help the clinician determine the extent of the work-up required and may help with treatment 
recommendations by aiding in the identification of factors that may complicate treatment. 
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Figure 2.1 Involuted or “hooded” vulva noted on physical examination 
 
 
Figure 2.2 Cystoscopic image of a dog with a paramesonephric remnant 
 
  
 Localization 
Acute bacterial pyelonephritis, prostatitis, and metritis are often associated with systemic signs 
such as fever, an inflammatory leukogram, lethargy, and anorexia.  In contrast, patients with 
chronic prostatitis and pyelonephritis may not exhibit systemic signs and therefore it may be 
more difficult to localize the infection.  Localization of the UTI is important to optimize 
antimicrobial choices and duration of therapy (Chapter one, Table 1.2 Localization of Urinary 
Tract Infections). 
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 Diagnosis 
Diagnosis of a UTI is made based on information obtained from history, physical examination, 
urinalysis (including method of collection), and ideally urine culture and sensitivity.  
Cystocentesis is the method of choice for collection of urine samples, especially if a urine culture 
is anticipated.  Patients presenting with lower urinary tract signs (e.g., pollakiuria and stranguria) 
may make collection by cystocentesis difficult due to the small size of the urinary bladder.  
Alternative methods of urine collection may be acceptable if cystocentesis cannot be performed 
or is contraindicated (e.g., suspected transitional cell carcinoma of the urinary bladder or 
pyoderma of the ventral abdomen).  Urethral catheterization provides a superior sample 
compared with a free-catch voided sample, but requires more technical skill, especially in female 
patients.  Care should be taken during catheterization to prevent contamination from external 
structures by clipping surrounding hair and cleansing the external genitalia prior to the 
procedure.  Based on current recommendations, free catch urine samples are not acceptable for 
culture.
47
  Urinalysis and urine culture results should always be interpreted in light of the urine 
collection method.
48-50
 
 Urinalysis 
Urinalysis may be helpful in differentiating a urinary tract infection (UTI) from other disorders 
causing lower urinary tract signs (e.g., bladder neoplasia), making initial antibiotic 
recommendations, and in some cases identifying potential predisposing disorders (e.g., 
glucosuria and crystalluria).  Urine specific gravity can be variable in patients with a UTI.  Dilute 
or minimally concentrated urine may be observed in patients with concurrent disease 
predisposing to UTI (e.g., diabetes mellitus or hyperadrenocorticism), or may be observed if the 
infection involves the upper urinary tract.  With a UTI, hematuria and proteinuria are frequently 
observed on dipstick analysis.  The dipstick analyses for nitrite (bacteria) and leukocyte esterase 
(WBCs) are designed for human urine and are not reliable tests for canine and feline patients.
51,52
  
A urine sediment examination should be performed to identify pyuria and bacteriuria.  If urine is 
dilute or the patient is immunocompromised (e.g., suffers from hyperadrenocorticism or is 
receiving exogenous corticosteroids), it may be difficult to identify WBCs or bacteria on urine 
sediment examination.  Air-dried, stained sediment evaluations were more accurate than wet, 
unstained mounts for identification of bacteria when urine culture results were used as the gold 
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standard (sensitivity 82.8% and specificity 98.6%).
53
  This air-dried, stained technique is easily 
performed in practice by placing one drop of sediment on a glass slide, allowing it to air dry 
(spreading may be necessary if sediment is thick), and then staining the sample with a 
commercially available modified Wright’s stain (Diff Quik®).  It is important to remember, 
however, that a culture is required for definitive diagnosis, and will provide additional 
information (e.g., bacterial identification, number of organisms/ml of urine, and antimicrobial 
susceptibility results). 
 Urine culture 
Although clinical signs and urinalysis findings may increase the index of suspicion for a UTI, a 
urine culture is the definitive diagnostic test.  Ideally, the urine sample for culture should be 
obtained prior to starting treatment.  In patients already receiving antimicrobial therapy, it may 
be necessary to discontinue treatment for 3-5 days before collection of urine culture.  It is also 
important to consider storage and transport of samples for culture in practices where immediate 
culture processing is not possible.
54,55
  Sterile containers that do not contain additives or 
preservatives should be used.  Commercially available urine collection kits may be acceptable 
for up to 72 hours if sample processing is delayed (Urotube Roche and Becton Dickinson Urine 
C&S Transport kit).
56,57
  Bacterial counts can increase in urine stored at room temperature within 
a few hours.  In refrigerated samples, quantitative bacterial counts differed after 6 hours of 
storage; however this was not associated with a change in interpretation of the clinical 
significance.  It is recommended that urine samples be cultured immediately; however, it is 
acceptable for urine to be refrigerated in a closed container for up to 6 hours prior to culture.
54
  
Alternatives to sending a urine sample to a commercial laboratory for culture include using a 
calibrated bacterial loop (0.01 or 0.001 ml volume) to inoculate blood or MacConkey’s agar 
plates in house.  Culture plates are then incubated for 24 hours at 37°C and if a significant 
numbers of colonies are produced in light of the urine collection method, the plate can be sealed 
and shipped to a microbiology laboratory for bacterial identification and antimicrobial sensitivity 
testing.  In most cases a quantitative urine culture will aid interpretation of results.  In addition to 
bacterial numbers/ml of urine, knowledge of the normal flora may also be helpful in determining 
contamination versus infection when methods other than cystocentesis are used (Chapter one, 
Table 1.1 Commensal bacterial genera in the urogenital tract of dogs). 
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 Contamination 
Bacteriuria is expected in patients with UTI, however bacteriuria may also be observed in 
healthy dogs and cats if the urine sample has been contaminated with normal flora and/or 
pathogens from the distal urethra/urogenital tract or if the urine sample contacts a contaminated 
surface.  Certain organisms are known to be commensal within the lower urinary tract and 
therefore knowledge of the organism and urine collection method may help determine 
contamination versus UTI.  There is however overlap between normal flora and potential 
pathogens.  Bacterial contamination of urine usually occurs when collecting a voided sample, but 
can also occur during urethral catheterization or be associated with collection of urine from a 
contaminated surface (e.g., cage floor, examination table).  It is important to differentiate urine 
contamination from a UTI since the former does not need to be treated.  Contamination can be 
ruled out by repeating a urinalysis with urine obtained via cystocentesis or by performing a 
quantitative urine culture on the voided or catheterized sample.  Depending on the method of 
urine collection, the number of bacterial colony-forming units (cfu)/ml of urine will vary 
between contamination and UTI (Table 2.1).  As stated previously, free catch urine samples are 
not recommended for culture and sensitivity and should only be performed when cystocentesis is 
not possible or recommended (e.g., transitional cell carcinoma or patients with bleeding 
disorders).   
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Table 2.1 Significance of Quantitative Urine Cultures in Dogs and Cats Based on Collection 
Method* 
 
  Significant Borderline Contaminant 
METHOD OF 
COLLECTION Dogs Cats Dogs Cats Dogs Cats 
Cystocentesis ≥1000 ≥1000 100-1000 100-1000 ≤100 ≤100 
Catheterization ≥10,000 ≥1000 1000-10,000 100-1000 ≤1000 ≤100 
Midstream voiding †  ≥100,000  ≥10,000 
10,000-
90,000 
1000-
10,000 ≤10,000 ≤1000 
Manual expression † ≥100,000  ≥10,000 
10,000-
90,000 
1000-
10,000 ≤10,000 ≤1000 
 
*Values are given in colony-forming units per milliliter of urine (cfu/mL).  Data represent 
generalities.  Occasionally bacterial UTI may be detected with fewer organisms (i.e., false-
negative results). 
† For midstream voiding and manual expression, the contamination level may be 10,000 cfu/mL 
or higher (i.e., false-positive result).  These samples should not be used for routine diagnostic 
culture. 
From Pressler B, Bartges JW:  Urinary Tract Infections.  In Ettinger, editor: Textbook of 
Veterinary Internal Medicine, ed 7, St Louis, 2010, Saunders, pp 2037. 
 
 Antimicrobial susceptibility testing 
Ideally, antimicrobial administration should be based on results from culture and susceptibility.  
Unnecessary or inappropriate usage of antibiotics can lead to antimicrobial resistance or delay 
the diagnosis of a non-infectious cause of lower urinary tract signs.
47
  In addition to susceptibility 
results, the route and ease of administration, potential adverse effects, cost, and concentration in 
the urine (or other targeted tissues e.g., prostate, kidney) should be considered when choosing an 
antibiotic. 
 Kirby-Bauer technique 
Agar disk diffusion (Kirby-Bauer) is a form of antimicrobial susceptibility testing.  This test 
requires inoculation of a Mueller-Hinton agar plate with a standardized suspension of a bacterial 
isolate.  Paper disks impregnated with antibiotics are then placed on the plate and the plate is 
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allowed to incubate.  Bacterial growth is inhibited around the disk, and the zone of inhibition is 
compared to a standard identified for that antibiotic.  Results of the disk susceptibilities are 
usually listed as susceptible, resistant, and intermediate; varying degrees of susceptibility or 
resistance are not described.  Agar disk diffusion has been replaced by the microwell dilution 
technique described below.  Testing and analysis should be performed in accordance with 
recommendations from the Clinical and Laboratories Standards Institute (CLSI). 
 Minimum Inhibitory Concentration 
Determining the minimum inhibitory concentration (MIC) uses serial dilutions of an antibiotic to 
determine the lowest concentration that will inhibit bacterial growth.  This concentration is the 
MIC and although results are reported as susceptible, intermediate, and resistant, they usually 
also include the actual MIC followed by the breakpoints used to determine susceptibility.  The 
goal of the breakpoint is to predict clinical outcome for an individual patient.  Breakpoints are 
determined by a combination of information including the species, bacteria, disease, antibiotic, 
dose, route and frequency.  It is important to keep in mind that there are limited data available for 
veterinary medicine; therefore breakpoints are often determined by using information available 
from human breakpoints.   
A result reported as "susceptible" indicates a high likelihood of treatment success (>80%) with 
most antibiotics; "intermediate" indicates possible success in treatment with potential alterations 
in normal dosing, and a "resistant" result indicates that a clinical cure is unlikely to occur with 
that antimicrobial.  The result is considered susceptible if the MIC is in the breakpoint range or 
below, intermediate if it is at the high end of the breakpoint, and resistant if it is above the 
breakpoint. 
Urine antibiotic concentrations are usually more important than plasma concentrations when 
treating a UTI.  Minimum inhibitory antibiotic concentrations and the anticipated urine antibiotic 
concentration may be used to guide treatment choices.  Clinical efficacy is expected if urine 
concentration is maintained at greater than four times the MIC of the pathogen between doses 
(Table 2.2).
58
  For example, the MIC of ampicillin for a Staphylococcus organism is 
approximately 10 µg/ml.  The expected serum and tissue concentrations of ampicillin are 1-2 
µg/ml whereas the expected urine concentration of ampicillin is > 300 µg/ml.  Since the expected 
urine concentration is > four times the MIC, it is reasonable to expect the UTI will resolve with 
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ampicillin therapy.  Minimum inhibitory antibiotic concentration testing based on anticipated 
urine concentrations is not appropriate for deeper tissue infections (e.g., pyelonephritis, 
thickened bladder wall) where serum and tissue antibiotic concentrations are expected.   
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Table 2.2 Mean concentration of select antimicrobial agents in canine urine 
Drug 
 
Dosage † Typical Antimicrobial Activity Steady State Mean 
Urine 
Concentration  
Amikacin 5 mg/kg, SQ Staphylococci, some Streptococci, 
some enterococci, E. coli, Proteus 
spp., Klebsiella spp., Pseudomonas 
spp., Enterobacter spp. 
342 µg/mL 
Amoxicillin 11 mg/kg, PO q 8 hrs Staphylococci, Streptococci, 
enterococci, Proteus spp. 
202 µg/mL 
Ampicillin 26 mg/kg, PO, q 8 hrs Staphylococci, Streptococci, 
enterococci, Proteus spp. 
 309 µg/mL 
Amoxicillin/clavulanic 
acid 
12.5 mg/kg, PO, q 8 
hrs 
Staphylococci, Streptococci, 
enterococci, Proteus spp., E. coli, 
Klebsiella spp. 
201 µg/mL 
Cephalexin 30 mg/kg, PO, q 8 hrs Staphylococci, Streptococci, 
Proteus spp., E. coli, Klebsiella spp. 
225  µg/mL 
Chloramphenicol 33 mg/kg, PO Staphylococci, Streptococci, 
enterococci, E. coli, Klebsiella spp. 
124 µg/mL 
Enrofloxacin 5 mg/kg, PO, q 24 Staphylococci, some Streptococci, 
some enterococci, E. coli, Proteus 
spp., Klebsiella spp., Pseudomonas 
spp., Enterobacter spp. 
40 µg/mL 
Gentamicin 4-6 mg/kg, SQ, q 24 
hrs 
Staphylococci, some Streptococci, 
some enterococci, E. coli, Proteus 
spp., Klebsiella spp., Pseudomonas 
spp., Enterobacter spp. 
107 µg/mL 
Penicillin G 36,700 U/kg, PO Staphylococci, Streptococci, 
Proteus spp. 
295 µg/mL 
Tetracycline 18 mg/kg, PO, q 8 hrs Streptococci, some Staphylococci 
and Gram negatives at high urine 
concentrations 
300 µg/mL 
Trimethoprim/sulfadiazine 15 mg/kg, PO, q 12 
hrs 
Staphylococci, Streptococci, E. coli, 
Proteus spp., some activity against 
enterococci and Klebsiella spp. 
55 µg/mL 
† Doses listed were used in the studies calculating mean urine concentrations and may not be 
consistent with current guidelines for treatment recommendations.   
Adapted from Ling GV:  Therapeutic strategies involving antimicrobial treatment of the canine 
urinary tract.  J Am Vet Med Assoc 185 (10): 1162-1164, 1984 and Dowling PM: Antimicrobial 
therapy of urinary tract infections.  Can Vet J 37 (7): 428-41, 1996.  
PO, Per os ; SD, standard deviation and SQ, subcutaneous. 
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 Result interpretation 
Clinical and Laboratory Standards Institute (CLSI) is a committee which provides 
recommendations that are considered the gold standard for breakpoint determination.  To 
determine breakpoints, the committee examines pharmacokinetics, microbiology, 
pharmacodynamics, bacterial population, MIC distribution, and clinical trial results.  Veterinary 
laboratories (or a human laboratories with appropriate susceptibility panels for commonly used 
veterinary antibiotics) that follow CLSI guidelines should be used for culture and susceptibility 
testing. 
Depending on the laboratory, comparing antibiotics with similar susceptibility (e.g., cephalexin 
and cefazolin) may be necessary but requires making assumptions.  For example, when 
comparing cefazolin with cephalexin, cefazolin is typically administered intravenously every 8 
hours whereas cephalexin is typically administered orally every 8-12 hours.  It is also important 
to remember that in vitro culture and susceptibility results may not correlate with in vivo 
efficacy.  For example, regardless of the susceptibility results for Enterococcus, certain 
antibiotics including cephalosporins, trimethoprim-sulfamethoxazole, clindamycin, and 
aminoglycosides should always be considered resistant since these are not effective clinically 
and do not correlate with in vitro results.
59
 
In many cases, antibiotic susceptibility testing results provide a clear direction for treatment with 
an antibiotic that is orally administered, has few potential adverse effects, and reasonable cost.  
In some cases, susceptibility results demonstrate a high degree of bacterial resistance and route 
of administration, high cost, or potential adverse effects of the potentially effective antibiotic 
may be a concern.  Although MIC may be used as a guideline for antibiotic selection, veterinary 
breakpoints for most antibiotics in the urinary tract of dogs and cats have not been determined.  
When intermediate results are obtained, it may be possible to achieve a cure if no alternative 
antimicrobial exists.  This would most likely be achieved by using a higher dose of an 
antimicrobial that is excreted in the urine.  In resistant infections, requesting an expanded 
antimicrobial susceptibility profile (e.g., ceftazidime, carbenicillin, nitrofurantoin) may suggest 
alternative treatment regimes.  Most commercial bacteriology laboratories have a second and 
third tier of antibiotics for expanded susceptibility testing; however, high cost and parenteral 
administration may be trade-offs. 
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 Classifying Urinary Tract Infections 
 Recurrent UTI: Relapse versus reinfection 
The appropriate classification of a recurrent UTI can help the clinician modify therapy, identify 
predisposing factors, identify reasons for treatment failures, and identify the need for 
prophylactic therapies.  Recurrent UTIs can be defined as either relapses or reinfections.  A 
relapse is an infection cause by the same bacteria after clearance of the infection (confirmed by 
negative culture) that caused the original infection, and usually occurs within several days of 
cessation of treatment.  Relapses are most frequently associated with ineffective antimicrobial 
treatment.  This may be due to improper antibiotic usage (inappropriate selection, dose, duration, 
or poor owner compliance), emergence of drug-resistant pathogens, or failure to eliminate 
predisposing causes that alter normal host defense mechanisms and allow the persistence of 
bacteria.  Relapse UTIs may be associated with a higher degree of antimicrobial resistance 
compared to the original infection. 
The other type of recurrent UTI is a reinfection.  Reinfections occur when the initial infection 
was effectively treated (documented by negative culture after therapy and resolution of clinical 
signs) and repeat culture confirms another infection with a different bacterial species or strain.  
Typically the time between reinfections is greater than the time between relapses.  Reinfections 
usually indicate that host defense mechanisms are compromised.   
 Superinfection 
Superinfections occur when new bacteria colonizes the urinary tract during the course of 
antimicrobial treatment for a UTI or another infection.  These can be associated with urine 
diversion procedures (e.g., cystostomy, urethrostomy, and indwelling urinary catheters) and are 
not common. 
 Hospital-acquired UTI 
Urinary catheterization is often useful in the management of patients with urethral outflow 
obstructive disease, for monitoring urine production, or for patient cleanliness.  Several patient 
risk factors need to be considered when weighing the risk and benefit of placement of an 
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indwelling urinary catheter.  The risk of hospital-acquired UTI in canine patients increases by 
27% for every day an indwelling urinary catheter is in place.
4
  In addition, risk increases by 20% 
with every year of age, and increases in patients receiving antibiotics by 450%.
60
  Gender did not 
correlate with increased risk of UTI for indwelling catheterization; however male dogs may be at 
decreased risk following a single catheterization.
60,61
 
The overall risk of nosocomial bacteriuria in catheterized patients is 10%.
62, 63
  Attempts should 
be made to minimize iatrogenic UTI by avoiding indiscriminate use of urinary catheters, and 
using indwelling urinary catheters cautiously when pets are undergoing diuresis, are receiving 
immunosuppressive therapy, or are immunosuppressed.  In addition, appropriately using 
antimicrobials and using diagnostic and therapeutic techniques that minimize trauma and 
microbial contamination of the urinary tract can help minimize the chance of infection.
64
  
Whenever possible, intermittent catheterization is preferred to indwelling catheterization 
especially in patients that are immunosuppressed and/or already receiving antibiotic treatment.  
Previously used IV fluid bags that did not contain dextrose and are <7 days old can be used as 
part of a closed urinary system if sterile bags are not available since they are unlikely to be 
sources of bacterial contamination.
65
  
 Treatment 
Treatment recommendations for bacterial UTI are dependent on several factors and should be 
tailored to each individual patient.  Factors to consider include classification of the UTI (e.g., 
complicated/uncomplicated, relapse, reinfection, superinfection), location of infection (e.g., 
bladder, kidney, prostate), and concurrent complicating factors (e.g., systemic disease causing 
predisposition or poor response to therapy, underlying disease affecting antimicrobial selection).  
These factors affect both the duration of therapy and antimicrobial selection.  Additional 
considerations include side effects, cost and compliance.  Steps to follow for the ideal 
management of UTIs are listed in Table 2.3. 
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Table 2.3 Ideal steps to follow in the management of UTIs in dogs and cats 
1. Diagnosis should be determined on the basis of history, urine sediment, and ideally, urine 
culture and susceptibility results.  Rule out contamination in voided or catheterized 
samples with quantitative culture.  Cystocentesis is the ideal way to collect urine for 
culture. 
2. Select an antimicrobial agent based on culture and susceptibility.  Without culture and 
susceptibility results use air-dried sediment findings and Gram stain to guide antibiotic 
choice (e.g., cocci vs. rods). 
3. Re-culture urine (or at least examine the urine sediment) 3 to 5 days after antibiotic 
administration has begun.  Urine culture should be negative and/or there should be no 
WBCs in the urine sediment. 
4. Examine urine sediment or culture 3 to 4 days before discontinuing antibiotic treatment. 
5. Repeat urinalysis and culture 5-7 days after cessation of antibiotic therapy.  (Steps 4 and 
5 are especially important for recurrent UTI.) 
6. Patients with recurrent UTIs should undergo imaging studies (e.g., plain and/or contrast-
enhanced radiography and/or ultrasonography), a complete blood count, and serum 
biochemistry profile to determine whether they have local or systemic underlying 
predisposing factors. 
7. In frequent reinfections, low-dose nighttime antibiotic regimes or cranberry extract may 
be considered after the initial inflammation has been cleared up in response to standard-
dose antibiotic treatment. 
 
 Antimicrobial Therapy 
 Antimicrobial selection 
Inappropriate antibiotic dosages or unnecessary usage can lead to resistant organisms impacting 
not only the individual patient, but potentially bacterial resistance in other veterinary patients and 
owners.
16
  Antimicrobials that are excreted in the urine are the mainstay of UTI treatment.  Initial 
antibiotic considerations can vary somewhat based on opinion.  There is variation among 
recommendations and no consensus has been reached; therefore I recommend amoxicillin and 
cephalexin as initial treatment options.  Trimethoprim-sulfadiazine has been suggested as well, 
however based on potential side effects (e.g., hypersensitivity, immune-mediated effects and 
keratoconjunctivitis sicca) should be chosen with careful patient selection and owner education.  
When host defense mechanisms are compromised, previous or current susceptibility results 
indicate potential resistance, or when the infection involves the prostate or kidneys, second tier 
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antibiotic choices may be considered with selection on an individual basis.  Possible options 
include potentiated ß-lactams (e.g., amoxicillin-clavulanic acid), fluoroquinolones, or extended 
release cephalosporins (e.g., cefovecin).
66,67
  Second tier antibiotics are not recommended as a 
first line treatment for an uncomplicated UTI, without appropriate culture and susceptibility 
results.  However, these may be considered when rapid treatment is necessary to return to 
function, prevent systemic spread of bacteria, or when penetration into a specific tissue, such as 
the prostate is needed.  For penetration into prostatic tissue, antibiotics should be lipid soluble, 
not highly protein bound, and ionize at the pH of the prostatic tissue.  Good prostate gland 
penetration can usually be achieved with fluoroquinolones, trimethoprim-sulfa, and 
chloramphenicol. 
 Empirical antimicrobial therapy for uncomplicated UTI 
Dogs and cats with uncomplicated UTI are typically treated with a 7-14 day course of antibiotics.  
It is reasonable to assume that shorter durations of appropriate antibiotics (≤ 7 days) may be 
effective; however clinical trials are needed to further evaluate shorter duration treatments.
47
  It 
is always ideal to treat on the basis of urine culture and susceptibility results; however, economic 
constraints may preclude this in first time patients with suspected uncomplicated UTI.  In these 
cases, antimicrobial selection should be based on bacterial characteristics observed in the urine 
sediment (e.g., Gram positive vs. Gram negative, cocci vs. rods).  For example, if a Gram 
negative rod or bacillus is seen (e.g., E. coli, Enterobacter, Klebsiella or Proteus), 
cephalosporins would be a good option.  With Gram positive cocci (e.g., Staphylococcus or 
Streptococcus), amoxicillin and cephalosporin would be options.  There are disadvantages to 
consider with this technique.  For example, identification of Gram positive cocci could also be 
consistent with Enterococcus, and would be resistant to a cephalosporin.  Clinical signs should 
resolve within 48 hours with appropriate treatment.  Along with resolution of clinical signs, 
evidence of inflammation in urine sediment should also resolve in 3-5 days of antibiotic 
treatment. 
When empiric antibiotic treatment is used, instructions to owners regarding what to expect as 
well as follow-up plans are critical.  If presenting clinical signs do not resolve quickly, owners 
should be aware of the need for a follow-up urinalysis and culture and susceptibility.  Owners 
should also be aware of the importance of completing the entire antibiotic regime, even if signs 
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resolve early in the course of treatment.  Finally, owners should be instructed to observe their 
pets closely for signs of UTI recurrence after the treatment regime is complete.  Clear 
communication and understanding of the “game-plan” will result in 1) improved treatment 
outcome and 2) increased client willingness to return in cases of empiric treatment failures. 
 Short course/high dose protocols 
Due to concerns with owner compliance during longer treatment protocols, short course/high 
dose protocols have been proposed for the treatment of uncomplicated UTI in dogs.  In a recent 
study in dogs, a short course, high-dose of enrofloxacin (18-20 mg/kg once daily for three days) 
was as effective as traditional dose amoxicillin-clavulanate (13.75-25 mg/kg twice daily for 14 
days) in treating uncomplicated UTI.
68
  Preliminary evidence suggests this may be an effective 
option; however, additional research may be necessary to incorporate this into routine clinical 
practice. 
 Complicated UTI 
Antibiotic treatment of complicated UTIs should be prolonged (typically 4 weeks) and always 
based on urine culture and susceptibility results. It is possible that shorter duration of therapy 
may be effective in some or all clinical situations, however further studies are needed to provide 
more specific recommendations.
47
  One week into treatment and one week prior to discontinuing 
antimicrobials, re-evaluation of the urine sediment (+/- culture) can help evaluate response to 
therapy.  When effective, no bacteria or white cells should be observed on sediment exam.  
Recheck urine culture is again recommended 5-7 days after completion of therapy to confirm 
successful resolution of the UTI.  Prolonged treatment of a complicated UTI may be necessary to 
sterilize the urinary tract, but “buying time” to allow for correction of host defense mechanism 
abnormalities is another important consideration.  If host defense mechanism abnormalities are 
not corrected, it may be difficult to clear the current infection or, more likely, the patient will 
experience reinfections. 
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 Asymptomatic bacteriuria 
Identification of bacteria in the urine, with an absence of clinical signs is defined as 
asymptomatic bacteriuria.  Asymptomatic bacteriuria may be hospital-acquired in critically ill 
patients or patients with indwelling catheters, may be an incidental finding on culture, or may be 
associated with a disease that suppresses the normal inflammatory response.  E. coli is most 
commonly isolated in patients with asymptomatic bacteriuria.  Uropathogenic isolates from 
asymptomatic patients have been shown to express fewer virulence factors than those identified 
from patients with symptomatic UTI.
69
  In my opinion, asymptomatic bacteriuria should be 
treated when quantitative culture results suggest an actual infection rather than contamination 
(See Table 2.1).  Treatment of asymptomatic bacteriuria associated with lower numbers of 
bacteria in urine (i.e., numbers associated with contamination) may contribute to antibiotic 
resistance and colonization of the bladder with more pathogenic strains of bacteria.
11
  
Experimental urinary tract colonization of less pathogenic strains of E. coli have been evaluated 
in dogs as a potential treatment option for recurrent UTI, further suggesting that asymptomatic 
bacteriuria does not necessarily require treatment.
10
 
 Treatment Failures 
Treatment failures may either involve an inability to eradicate the current infection (persistent 
infection), relapses or reinfections.  Relapses and persistent infection are most commonly 
associated with antibiotic treatment failures whereas reinfections are most commonly associated 
with compromised host defense mechanisms (Table 2.4). 
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Table 2.4 Reasons for poor therapeutic response in dogs and cats with UTI 
1. Use of ineffective drugs or ineffective duration of therapy  
2. Failure of owner to administer prescribed dose at proper intervals 
3. Gastrointestinal tract disease, decreased bioavailability of a drug, conditions resulting in 
decreased drug absorption, or impaired renal concentrating ability resulting in decreased 
antibiotic concentrations in the urine  
4. Impaired action of drugs, either because bacteria are not multiplying or because they are 
sequestered in an inaccessible site (e.g., prostate, neoplasia, or uroliths) 
5. Failure to recognize and eliminate predisposing causes  
6. Presence of mixed bacterial infections in which only one of the pathogens is eradicated 
by antimicrobial therapy  
7. Iatrogenic reinfection caused by catheterization  
8. Development of drug resistance in bacteria  
  
 Antimicrobial resistance 
Multi-drug resistance (MDR) is becoming more commonly recognized in veterinary medicine.  
The urinary tract was the most common extra-intestinal source of MDR E. coli and Enterobacter 
in dogs accounting for 62 and 58% of the isolates, respectively.
11
  Twenty-seven percent of dogs 
with UTI had a urinary catheter and all but one was given antimicrobials while a urinary catheter 
was in place.
11
  Risk factors identified were underlying illness contributing to 
immunosuppression (97%), hospitalization for ≥ 3 days (82%), and surgical intervention 
(57%).
11
  Several canine retrospective studies evaluating UTI isolates and resistance are 
available.  One study found a significant increase in recurrent E. coli infections and increased 
resistance with all antimicrobials tested with the exception of tetracycline and trimethoprim-
sulfamethoxazole.
70
  Another study found an increase in fluoroquinolone resistance.
66 
 
Evaluation of Staphylococcus resistance found 100% of  isolates to be resistant to at least one 
drug and 77% showed MDR.
71
  Increased incidence of multidrug-resistant Enterococcus from 
the urinary tract has also been identified.
72
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 Inability to eradicate and/or recognize underlying causes 
Compromised local or systemic host defense mechanisms increase the risk of UTI and make 
treatment more difficult.  Although a transient breach in host defenses may result in a simple 
uncomplicated UTI, it is of utmost importance to identify and resolve potential underlying causes 
whenever possible.  Common systemic disorders known to predispose to UTI include chronic 
kidney disease, endogenous or exogenous glucocorticoid excess, diabetes mellitus, and 
hyperthyroidism.
24, 41, 42, 44
  Although some of these disorders may not be correctible, control of 
the underlying disease is often helpful.  Local disorders of the lower urinary tract also increase 
the risk of UTI.  Examples include anatomic abnormalities like a “hooded” or recessed vulva, 
ectopic ureter and urolithiasis.
73
  Systemic and local defense mechanism abnormalities are often 
ruled out with a complete minimum data base (e.g., complete blood count, chemistry, and 
urinalysis) and imaging, respectively. 
 Ancillary Prevention Therapies 
Ancillary therapies designed to prevent recurrent UTI are considered in patients where breaches 
in host defenses are present but are not correctable or in cases where an underlying cause for 
reinfection is not identified.  Care should be taken to treat any underlying infection prior to 
starting any prevention measures.  Owners should watch closely for clinical signs and be advised 
that frequent rechecks will be necessary to detect and treat any break through infections. 
 Prophylactic antimicrobial treatment (low dose protocols) 
Prophylactic antimicrobial treatment involves long-term daily administration of low-dose 
antimicrobials in order to inhibit or minimize uropathogen growth, thus decreasing the 
opportunity for bacterial adhesion and colonization of the uroepithelium.  Unfortunately there are 
no studies in dogs that have evaluated the efficacy and adverse effects of these protocols.  Due to 
risk of selecting for resistant organisms, prophylactic, low-dose antibiotic administration should 
be reserved for refractory cases and then only after all attempts to resolve correctable problems 
have been exhausted. 
Prophylactic, low-dose antibiotic treatment should only be initiated after standard dose antibiotic 
treatment has been successful (negative urine culture).  Best results are expected with drugs that 
are excreted in the urine.  Other considerations should include potential side effects of the drug 
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and previous culture and susceptibility results.  Commonly used protocols include 
fluoroquinolone, cephalosporins, or ß-lactam antimicrobials.  If E. coli or enterococci is 
previously cultured, nitrofurantoin is another option.  The dose used should be one-half to one-
third the therapeutic daily dose administered immediately after the last voiding before bedtime.  
This protocol is typically recommended for a minimum of 6 months and urinalysis and culture 
should be performed every 4-8 weeks.  If at any point during the treatment a UTI occurs, it is 
treated as a complicated UTI.  Prophylactic, low-dose therapy can be re-started after the 
reinfection has been resolved.
15
  
 Cranberry extract  
Proanthrocyanidins, specifically A-type isoforms, found in cranberries inhibit E. coli attachment 
by blocking interaction of bacterial P-fimbriae with the surface of uroepithelial cells.
74,75
  Canine 
studies evaluating the efficacy of cranberry extract are limited; however, some in vitro data show 
promising results.  One study demonstrated that E. coli in urine from dogs receiving oral 
cranberry extract (CE) had decreased ability to agglutinate to human red blood cells (Nutramax 
Laboratories, Inc. Crananidin™).75  Similarly a second study (see Chapter 3) demonstrated that 
in urine from dogs receiving oral CE
 (Vetquinol, Paxon™), E. coli had decreased ability to 
adhere to Madin-Darby Canine Kidney (MDCK) cells.
76
  Based on these in vitro studies, oral 
administration of cranberry extract may help reduce E. coli reinfections in patients with 
compromised host defense mechanisms.  Due to large variations of the active compound in over-
the-counter products, it may be of benefit to use the products evaluated for canine use
 
(Crananidin™ or Paxon™) dosed according to manufacturer recommendations.  Chapter 3 will 
further discuss the study performed as part of this thesis on the use of CE (Vetquinol, Paxon™). 
 Urinary antiseptics 
The most commonly used urinary antiseptic is methenamine which is converted to formalin in an 
acidic environment.  Methenamine may be considered in patients with recurrent infections or 
patients with potentially untreatable or unresolved breaches in immunity.  Just as with the use of 
cranberry extract, this prophylactic treatment is not recommended as a sole treatment for UTIs.  
Methenamine should only be used in conjunction with antibiotics for the treatment of current 
infections or as a preventative once the previous UTI has been cleared.  Usage should be avoided 
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in patients on treatment with sulfonamides or medications that cause alkaline urine.  Urine 
acidifiers added to methenamine cause acidic urine that can also decrease activity of 
fluoroquinolone and aminoglycoside antibiotics.  High doses can cause irritation to bladder 
mucosa; however this is more common in people than dogs. 
 Miscellaneous treatments 
Urinary acidifiers are not recommended as adjunctive treatment of UTI, since dogs and cats 
usually have an acidic pH and many factors (e.g., diet, concurrent disease, and certain bacteria) 
can cause alkaline urine and prevent activation.  A possible exception is concurrent use with 
methenamine.  Similarly, antimicrobial agents instilled directly into the urinary bladder are not 
recommended as they have not been shown to be effective.  In addition, potential complications 
could include bladder rupture and absorption of toxic concentrations of drugs through an 
inflamed bladder wall.  Antibiotic administration via a urinary catheter would only be of use in 
patients with urine retention disorders that require intermittent urethral catheterization to empty 
the bladder (e.g., upper motor neuron bladder disorders). 
 Complications of Urinary Tract Infections 
 Polypoid cystitis 
Polypoid cystitis occurs when uroepithelial proliferation is severe; resulting in mass-like lesions 
or diffuse thickening of the bladder wall associated with intramural accumulation of 
inflammatory cells.
77, 78
  Typically these lesions are identified by ultrasound or contrast 
radiographs during evaluation for predisposing factors (Figure 2.3).  If bladder wall thickening 
is present in the apex of the bladder and the lesion does not have prominent vascular flow on 
Doppler, polypoid cystitis is likely; however histopathology is required for definitive diagnosis.  
Proteus is commonly associated with the development of polypoid cystitis.
77,78
  Polypoid lesions 
often contribute to patient discomfort but may also serve as a nidus for relapse.  Medical 
management involving treatment of the UTI with appropriate antimicrobials may resolve the 
lesions.  Surgical excision and biopsy of localized lesions should be considered to decrease 
duration of medical therapy and to rule out TCC as the possible etiology.
77
  If cystoscopy is 
available, it may provide a less invasive option to collect samples for histopathology and culture. 
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Figure 2.3 Ultrasound image of a mass-like lesion in the apex of the bladder consistent with 
polypoid cystitis 
 
 
 Emphysematous cystitis and pyelonephritis  
Gas can be produced in the bladder wall or lumen and/or renal pelvis as a consequence of 
bacterial infection and most commonly occurs in dogs and cats with diabetes mellitus since the 
presence of glucosuria provides a fermentable substrate (Figure 2.4).
79
  Emphysematous cystitis 
is usually caused by E. coli infection, but Proteus, Clostridium, and Aerobacter aerogenes 
infections have also been reported.
79,80
  Therapy should be similar to treatment for a complicated 
UTI with additional treatment to resolve glucosuria if present.  Emphysematous pyelonephritis 
can occur for the same reasons as emphysematous cystitis, and appears to be a rare complication 
in veterinary medicine.  
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Figure 2.4 Lateral abdominal radiograph of a newly diagnosed diabetic cat with 
emphysematous nephritis and cystitis secondary to an E. coli and Streptococcus sp. UTI 
 
 
 
 Magnesium ammonium phosphate (struvite) urolithiasis 
Urolithiasis may damage the uroepithelium and predispose dogs and cats to UTI, but infections 
may also result in urolith formation.  Struvite urolith formation most frequently occurs secondary 
to an infection involving a urease producing bacteria such as Staphylococcus, Proteus, and less 
commonly Corynebacterium, Klebsiella, and Ureaplasma.  Urease hydrolyzes urea to ammonia, 
which buffers urine hydrogen ions, forming ammonium ions and increasing urine pH leading to 
an increased amount of dissolved ionic phosphate.  The increased concentration of ammonia and 
phosphate along with increased urine pH sets the stage for struvite crystal formation, and 
inflammatory debris associated with the UTI may serve as a nidus for urolith formation.  
Differences exist between canine and feline patients with regard to struvite urolith 
pathophysiology.  In canine patients, > 90% of struvite uroliths occur secondary to a UTI, 
however in feline patients, struvite uroliths are more likely to be sterile.  If medical dissolution 
therapy is not an option for struvite urolithiasis or if other complicating factors exist (such as 
other underlying host defense compromise or urinary obstruction), surgical removal may be 
indicated and the uroliths and a piece of bladder mucosa should be analyzed and cultured.
81,82
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 Pyelonephritis 
Most commonly pyelonephritis (infection of the renal pelvis) occurs secondary to an ascending 
UTI.  The kidneys are typically protected from ascending bacterial infection by long ureters 
which keep urine flow mostly one-way with peristalsis, the valve-like nature of the 
vesicoureteral junction that prevents reflux of urine during voiding, and a relatively hypoxic 
environment present in the renal medulla.  Risk factors for pyelonephritis, similar to those for a 
lower UTI, include ectopic ureters, renoliths, obstructive uropathies, urine retention disorders, 
and systemic immunocompromise.  In comparison to a typical lower UTI presentation, acute 
pyelonephritis may be associated with signs of systemic illness (lethargy, anorexia, fever, 
inflammatory leukogram, lumbar pain).  In addition, renal azotemia and urine concentrating 
deficits may exist with bilateral pyelonephritis.  If present, pyelectasia is commonly observed on 
ultrasound and a skilled ultrasonographer may be able to perform pyelocentesis to obtain 
samples for cytology and culture.
83
  If pyelonephritis is suspected or confirmed, the UTI should 
be treated as a complicated UTI with a minimum of 6-8 weeks of antibiotics.  Regular ultrasound 
monitoring should be performed to evaluate for resolution of pyelectasia, monitor for 
progression, or identification of other underlying causes of pyelectasia (e.g., obstructive 
ureterolith) that may require additional antibiotic therapy or alternative therapies.
19
  It has also 
been suggested that treatment duration of 4-6 weeks may also be adequate.
47
  As with other 
suggested protocols, further research may help determine if a shorter duration may also be 
effective. 
 Prostatitis 
The prostate is exposed to commensal microorganisms from the distal urethra and with this 
constant exposure comes risk of infection.  Bacterial prostatitis can occur as a diffuse infection or 
as a prostatic abscess.  A healthy prostate gland has local protective mechanisms that typically 
prevent colonization and infection and it is likely that bacterial prostatitis occurs due to a 
breakdown in the normal host defenses or secondary to other prostatic pathology (e.g., prostatic 
neoplasia, or benign prostatic hyperplasia).
25, 26
  In patients with suspected prostatic disease, 
catheterization for retrieval of prostatic fluid or washings with prostatic massage, ejaculate or 
prostatic aspirates may be considered in addition to cystocentesis for culture evaluation.
84
  When 
treating chronic prostatitis, it is necessary to treat with antibiotics that penetrate the blood-
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prostate barrier such as fluoroquinolones, trimethoprim-sulfa combinations, and 
chloramphenicol.  Treatment should be continued initially for 4 weeks; however extended 
therapy (6 weeks) may be needed.
47,85
  In patients with acute prostatitis, disruption of the 
prostatic capsule should allow any antibiotic concentrated in the urine to penetrate into the 
prostatic tissue; however, as the inflammation subsides with treatment, antibiotic penetration 
may become an issue.  In patients with abscessation of the prostate, surgery or ultrasound guided 
drainage should be considered.
86,87
  In intact male dogs, castration may be beneficial in resolving 
chronic bacterial prostatitis.
88
  Recurrence is possible, especially if underlying conditions are 
present.   
 Prognosis 
Most UTIs are uncomplicated and appropriate antibiotic treatment rapidly clears the infection 
resulting in a good prognosis.  However, the prognosis for a complicated UTI may be guarded.  
It is of utmost importance to correct underlying defects in host defenses whenever possible to 
achieve the best outcome with a complicated UTI.  Following protocols for ideal UTI 
management and monitoring will improve treatment success and decrease the incidence of 
recurrent UTI.  
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Chapter 3 - Cranberry Extract Reduces Adhesion of 
Uropathogenic E. coli to Canine Uroepithelial Cells 
 Introduction 
Urinary tract infection (UTI) caused by Escherichia coli (E. coli) species is common in pet dogs.  
E. coli organisms caused ~ 45% of all UTI infections in a general referral population of dogs,
4
 
however in dogs with illnesses that convey a higher risk of UTI, such as diabetes or 
hyperadrenocorticism, the prevalence of E. coli UTI  is greater still and approached 70%.
42
  In 
dogs presenting to a referral institution for persistent or reinfection UTI, 71% were found to have 
an underlying disorder thought to be associated with the recurrent UTI.
89
  In this study, clinical 
resolution of the UTI was only achievable in 35% of these cases.
89
  This data suggests there are 
patients “at risk” who may benefit from UTI prevention. 
One potential strategy to address UTI prevention in at-risk patients involves the use of cranberry 
products to reduce UTI incidence.  Cranberry fruit juice and cranberry-derived products have 
been reported to have antibacterial properties, although the basis for the actions of cranberry is 
not completely understood.  Oral administration of cranberry extract (CE) alters urine pH and 
increase urinary excretion of hippiuric acid.
90
  These alterations had previously been postulated 
as mechanisms of action for CE; however more recent  research has questioned these 
mechanisms.
90
  Currently proanthrocyanidins (PACs), specifically A-type isoforms, contained in 
cranberry juice are proposed to inhibit E. coli attachment by blocking interaction of bacterial 
fimbriae with the surface of uroepithelial cells, effectively preventing bacterial adherence and 
reducing colonization of the urinary epithelium.
74,90
  Cranberry extract (CE) is a complex organic 
mixture, the composition of which varies with the methods used to extract and concentrate the 
cranberry products.  Other compounds found in cranberry extracts including 1-O-
methylgalactose, prunin, and phloidzin also have demonstrated anti-adherence activity in vitro.
91
  
Drinking cranberry juice was shown to effectively reduce the incidence of bacteriuria in human 
subjects.
92
  A study of a commercially available cranberry powder used in an in vitro study found 
inhibition of E. coli adherence to bladder or vaginal epithelial cells.
90
 
Research evaluating CE efficacy in veterinary medicine is limited.  A study of urine from dogs 
fed a CE product using a modified MIC method, found no significant inhibition of bacterial 
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adherence to canine uroepithelial cells.
93
  These results are difficult to evaluate as the method 
used to determine bacterial adherence was not detailed and it was not clear whether the urine was 
analyzed for A-type proanthrocyanidins and other bioactive compounds contained in CE. 
Previous human studies have evaluated cultured bladder, vaginal epithelial, and urothelial cells 
for adhesion studies.
90,91
  Madin-Darby Canine Kidney (MDCK) cells are a well-characterized 
canine uroepithelial cell model. MDCK cells were established in 1958 from the kidney of a 
normal dog and have become a mainstay model for epithelial cell research.
94
  Earlier work used 
the MDCK cell model to study infection by uropathogenic bacteria, including E. coli.
95, 96
 
Current treatment strategies focus on eradication of established infections and rely almost 
exclusively on the use of antibiotics to establish a cure.  Evidence for antibiotic resistance among 
common bacterial organisms does exist.  This underscores the potential for therapeutic failure 
and persistent infection.  Further, an expert panel has expressed concerns about the broader 
dangers posed by injudicious and improper use of antibiotics to treat canine infections.
16
  Given 
these concerns and the limitations of antibiotic therapy, new strategies for treatment and 
prevention of urinary tract infections in dogs need to be developed.   
Effective alternatives to antibiotics may offer a partial solution to the problem of antibiotic 
resistance, and use of compounds, such as CE, are likely to play an increasingly important role in 
UTI prevention in dogs.  This study assessed the efficacy of a commercial CE product
 
(Vetoquinol, Paxon™) to inhibit bacterial adhesion to canine uroepithelial cells.  The hypothesis 
was that purified CE would inhibit bacterial adhesion to canine uroepithelial cells. 
 Materials and Methods 
 Dogs 
Five client-owned female dogs, (three spayed and two intact) were enrolled in the study.  At 
enrollment, all dogs were determined to be healthy based on medical history and a complete 
physical examination.  The dogs also had no previous significant medical history, including no 
signs of lower urinary tract disease.  Each dog received an oral CE supplement
 
(Vetquinol, 
Paxon™) daily for 30 days.  The CE supplement was administered once daily by mouth at the 
dose specified on the product label (10-20 mg/kg). For all dogs, voided urine samples were 
38 
 
collected before (PRE) and 4 weeks (30-DAY) after beginning CE supplementation. The 
protocol was approved by the Kansas State University Institutional Animal Care and Use 
Committee.  Dog owners were dispensed a 30-day supply of a supplement
 
that contained 100 mg 
CE/tablet.   
 Urine samples 
Urine samples were collected at-home by dogs’ owners and refrigerated until submitted to the 
laboratory for processing.  Upon receipt in the laboratory, urine samples were prepared for 
storage by centrifugation at 3500 rpm for 5 min to sediment particulate matter.  The supernatant 
was drawn off using a sterile Pasteur pipette and vacuum filtered using a commercial filtration 
unit with a 0.22 µm polyethersulphone (PES) filter (Steriflip Filter Unit, Millipore).  The filtered 
urine was collected in a sterile 50 ml conical tube and frozen at -20°C until used in experiments.  
 Madin-Darby Canine Kidney (MDCK) cells 
Madin-Darby Canine Kidney (MDCK) cells were maintained in Eagle’s minimum essential 
medium (MEM) plus 10% (v/v) heat inactivated fetal bovine serum and supplemented with 1 
mM sodium pyruvate and 1% (v/v) antibiotic solution (penicillin-streptomycin-amphotericin B).  
Stock cultures of cells were propagated in 75 cm
2
 plastic flasks at 37° C in a humidified 95% 
O2/5% CO2 atmosphere and passaged as needed. 
 Propagation of uropathogenic E. coli strain 
An UPEC E. coli strain isolated from a human clinical UTI was used for adhesion experiments.  
The E. coli strain was grown on blood agar plates at 35°C for 24-48 hours.  After the appearance 
of distinct bacterial colonies, plates were sealed and stored at 4°C until needed for experiments.  
For experiments, an E. coli colony was picked, streaked, and incubated at 35°C overnight on 
colony forming agar (CFA) to promote fimbrial expression.
91
  Colony forming agar was prepared 
with casamino acids (10g/L), yeast extract (1.5 g/L), MgSo4 (0.05 g/L), MnCl2 (0.005 g/L) and 
2% (v/v) agar per liter water, as previously described.
92
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 Adhesion assay 
The efficacy of CE to inhibit bacterial adherence to MDCK uroepithelial cells was evaluated 
using an in vitro adhesion assay modified from Turner et al.
91
  Adhesion assays were performed 
as follows. 
 Preparation of bacterial suspension  
E. coli colonies grown overnight on CFA agar were picked and suspended in 200 μl saline to a 
standard bacterial concentration of ~ 3x10
6
 CFU/ml, which was determined by absorption 
spectroscopy (between 0.075 and 0.085 AU at 650 nm).  
 Preparation of MDCK cells  
The MDCK cells that had been grown to confluence at 37°C were prepared in 96-well plastic 
plates.  Immediately before being used in the adhesion assay, MDCK cells were fixed with 
methanol.  For fixing, culture media was discarded and each well washed with 100 μl phosphate 
buffered saline. The wash was discarded and the plate tapped dry on absorbent paper.  Methanol 
(100 μl) was added to each well and allowed to remain for 2 minutes.  The methanol was 
discarded and the plate tapped dry on absorbent paper.  The plate was dried in a laminar flow 
hood for 10 minutes. 
 Preparation of test samples  
To prepare samples for testing, an aliquot of the bacterial suspension was mixed 1:10 with urine 
samples (either PRE or 30-DAY).  To block mannose-dependent Type 1 fimbriae, a 96-well 
plastic plate was prepared by adding 50 μl of the test sample (urine + bacteria) to 150 μl 
modified MEM media supplemented with 2.5% methyl-mannose (final volume 200 μl/well) and 
the plate incubated at 25°C for 30 min. 
 Adhesion phase  
After incubation with mannose for 30 minutes, a 100 μl aliquot of the test sample containing E. 
coli was added to 96-well microplates containing methanol-fixed MDCK cells.  The microplate 
was centrifuged at 500 rpm for 2 min to collect fluid into the bottom of the well and the plate 
incubated for 60 min at 35°C to permit bacterial attachment.  After 60 minutes, non-adhered 
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bacteria and media were removed by aspiration and wells were rinsed three times with 200 μl 
PBS.  After the wash step, 200 μl fresh RPMI + 5% heat inactivated FBS were  added to each 
well and the plates incubated at 35°C for 4 hours to grow attached bacteria to detection level.  A 
standard curve was prepared for each plate by making serial dilutions of a suspension containing 
1x10
7
 bacteria.  Absorbance at 650 nm was determined for each well at 0 hr (baseline value) and 
4 hr using a plate reader.  The difference in absorbance between 0 and 4 hr represented growth of 
bacteria that had been adhered at 0 hr.  The initial concentration of adhered bacteria in each well 
was determined using known concentrations obtained from standard curve information.  All 
samples were analyzed in duplicate.   
 Direct killing assay 
Cranberry extract was assessed for bacteriostatic or bactericidal effects by exposing urine to 
bacteria in the absence of MDCK cells.  The direct killing assay was performed similarly to the 
adhesion assay.  Preparation of the bacterial suspension and the test samples was performed as 
described.  To assess direct effects on bacterial growth or viability, the plate assay was 
performed as described for the adhesion assay except that the plates did not contain MDCK cells 
and the aspiration step was eliminated.  After incubation with mannose for 30 minutes, a 100 μl 
aliquot of the test sample containing E. coli was added to 96-well microplates.  The microplate 
was centrifuged at 500 rpm for 2 min to collect fluid into the bottom of the well.  A standard 
curve was prepared for each plate by making serial dilutions of a suspension containing 1x10
7
 
bacteria.  The plate incubated for 60 min at 35°C to permit bacterial growth.  Absorbance at 650 
nm was determined for each well at 0 hr (baseline value) and 4 hr using a plate reader.  The 
difference in absorbance between 0 and 4 hr represented growth of bacteria.  PRE and 30-DAY 
samples from each dog were pooled for use in the direct killing assay.  In addition to PRE and 
30-DAY urine samples, a control (bacteria in phosphate-buffered saline) was evaluated. 
 Statistical Analysis 
A repeated measures ANOVA was used to evaluate the effect of oral cranberry extract 
supplementation on bacterial adhesion.  The model outcome was the difference in bacterial 
adhesion count between pre (PRE) and post (30-DAY) treatment samples.  The analysis 
accounted for the effects of dog and replicate.  A commercial software program was used
 
(Stata 
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12) was used for all analyses (StataCorp. 2011. Stata Statistical Software: Release 12. College 
Station, TX: StataCorp LP). 
 Results 
 Study dogs 
Five female dogs [Labrador Retriever (n=2), Shetland Sheepdog (n=2), and Boston Terrier 
(n=1)] completed the 30-day study.  PRE and 30-DAY urine samples were obtained from all 
enrolled dogs.  The mean weight was 16.2 kg (35.6 lbs) with a range from 5.9 – 29.5 kg (13 – 65 
lbs).  The mean age was 9 years with a range from 1-14 years.  No adverse effects attributable to 
CE supplementation were reported and all dogs remained healthy throughout the study period.  
Owner compliance with CE supplementation was 100% with no missed doses reported.  All 5 
dogs readily consumed the tablets containing the CE supplement. 
 Bacterial adhesion assay  
PRE and 30-DAY urine samples from each dog were assayed in duplicate in 4 separate assays.  
Compared with PRE urine, bacterial adhesion was reduced in 30-DAY urine in each of the 5 
dogs.  The magnitude of reduction ranged from 2.4 – 61% (mean 27%) across individual dogs 
(Figure 3.1).  When PRE and 30-DAY urine samples were compared, the combined results for 
all dogs (n=4 separate assays) showed that bacterial adhesion was significantly reduced in 30-
DAY samples (p=0.015) (Figure 3.2).  
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 Figure 3.1 Effect of CE Supplement on Bacterial Adhesion in Urine-Individual Dogs 
 
 
This figure represents N=4 separate assays, for each of the five dogs.  The PRE is compared to 
30-DAY for each dog.  The bars represent the standard deviation.   
 
Figure 3.2 Effect of CE Supplement on Bacterial Adhesion in Urine-Combined Data 
 
 
This figure shows the overall inhibition of bacterial adherence observed in urine samples from all 
dogs.  Compared with pre-treatment urine, urine for dogs that received CE supplementation for 
30 days had 30% overall reduction in bacterial adhesion.  * Denotes statistical significance from 
PRE-TX (P = 0.015). 
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 Direct killing assay  
The results of the direct killing assay demonstrated an inhibitory effect of urine on bacterial 
growth.  Bacterial growth was reduced by 13% and 18%, respectively, in PRE and 30-DAY 
urine samples compared with saline controls.  However, there was no difference in bacterial 
survival and growth when PRE and 30-DAY urine samples were compared (Figure 3.3). 
 
Figure 3.3 Direct Killing Assay Demonstrates Inhibitory Effect 
 
 
This figure shows the inhibitory effect of urine on bacterial growth. Compared with the saline 
control bacterial growth is reduced in pooled urine samples from dogs that received CE 
supplementation.  There was no significant difference between bacterial growth in PRE (n=3) 
and 30-DAY (n=4) samples. 
 Discussion 
Urinary tract infection by uropathogenic E. coli (UPEC) involves a complex process of bacterial 
adhesion and invasion.  Adhesion is mediated in part via structures, such as mannose-sensitive 
Type 1 fimbriae and non-Type 1 fimbriae such as Types P, S, and F1C.
97,98
  It is reported in 
people that over 90% of pathogenic and non-pathogenic E coli strains express Type 1 fimbriae.
97
  
In people, non-Type 1 fimbriae are associated with UPEC strains that exhibit tropisms within the 
urinary tract; Type P fimbriae, for example, are often expressed by UPEC strains that cause 
pyelonephritis and acute prostatitis.
99
  CFA agar in the present study was used because E. coli 
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grown under these conditions to promote P fimbriae expression by E. coli colonies.
91
  
Polymerase chain reaction testing of E. coli grown on CFA agar would have been needed to 
confirm P fimbriae gene expression but was not performed.
91
  To further ensure that any 
observed bacterial adherence was mediated via non-Type 1 fimbriae typically expressed by 
UPEC, bacteria were incubated with mannose to block Type 1 and mannose-sensitive adhesion 
mechanisms.  Adhesion observed in the presence of mannose indicates that adhesion involved 
mannose-insensitive mechanisms, which typically mediate UPEC infection. 
In the present study, the goal was to investigate an overall effect of oral CE supplementation on 
bacterial adhesion in canine urine.  The major finding was that E. coli adhesion to canine 
uroepithelial cells was reduced on average by 27 % in urine from dogs that had received the CE 
supplement.  The adhesion assay detects E. coli bacteria that remained adhered to MDCK cells 
despite mannose-blockade and extensive washings.  Bacterial persistence under such conditions 
is likely the result of pathological attachment mechanisms, rather than non-specific interaction 
with the MDCK cell surface.  It is possible that bacterial growth in the last step of the adhesion 
assay could be impaired if CE exerted a bacteriocidal or bacteriostatic effect.  This possibility 
was addressed in the direct killing assay, which showed a minor bacteriocidal effect of urine but 
no direct bacterial killing by CE.  The anti-bacterial effects of urine on the UPEC strain used in 
these experiments is explained by the fact that normal urine has biological and physiochemical 
characteristics that prevent bacterial growth.
23
  However, although bacterial growth was 
suppressed in PRE and 30-DAY urine samples compared with saline controls, there was no 
difference in bacterial growth when PRE and 30-DAY samples were compared. 
A previous canine study found that a CE inhibited bacterial adherence to primary cultures of 
uroepithelial cells, but that urine from dogs given an oral CE preparation did not have a similar 
effect.
93
  Dogs fed the CE preparation were only treated for 7 days prior to analysis, and it is 
possible that a longer period of administration was needed for an effect to become apparent.  
However, it was reported in a recent abstract that E. coli in urine from dogs receiving oral CE
 
had decreased ability to agglutinate human red blood cells as early as 7 days after CE 
supplementation.
75
  In contrast, in a human study, reduction of bacteriuria after ingestion of 
cranberry juice was not evident until 1-2 months of treatment.
92
  While the duration of 
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supplementation may have some role in determining the onset of the CE effect, it is also likely 
that other factors are involved. 
The concentration of PAC equivalents is a factor that influences the anti-bacterial effects of CE 
supplements.  A human study evaluating dose effect of ingested cranberry powder in urine on a 
human epithelial cell line found a clear dose-dependent inhibition of E. coli; the effect increased 
with the amount of PAC equivalents consumed.
100
  An in vitro study found E. coli adherence to 
uroepithelial cells to be inhibited in a linear, dose-dependent manner over PAC concentration 
range of 5 to 75µl/ml.
90
  Ideally the concentration of PAC’s would have been measured in 30-
DAY urine samples and the CE tablet in the present study to determine optimal CE doses.  
Comparison between the current and previous studies cannot be made easily since PAC’s were 
not measured in the CE product or in the urine samples tested.  However, the dosing protocol 
used in the current study was sufficient to induce a CE effect in all 5 dogs studied.  After the 30 
day treatment period, urine from all dogs studied presumably contained enough PAC equivalents 
to exert an inhibitory effect on bacterial adhesion. 
The current study was not designed to be a clinical study, and thus it was not the intention to 
detect differences between individual dogs.  However, it is interesting to note that there were 
obvious differences in the CE effect between individual dogs.  The reason(s) for such 
pronounced individual differences in the CE effect are not known.  Some of the difference 
between treated individuals could be related to the ingested dose of CE.  The CE was 
administered using product label guidelines and tablets were not divided.  Individual dogs 
received between 10-20 mg/kg, with the dose being rounded to the nearest tablet size.  
Differences in gastrointestinal absorption, CE metabolism and renal excretion could also 
contribute to the individual differences observed.  Additional studies would be needed to 
investigate the physiological and pharmacological basis for these findings.  Future studies could 
further evaluate the clinical efficacy of CE supplementation to reduce E. coli UTI as well as 
identify individuals most likely to benefit from treatment.   
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 Conclusion 
The current in vitro study shows that urine from dogs that received an oral dose of CE for 30 
days dramatically reduces bacterial adhesion to canine uroepithelial cells.  These results suggest 
that oral CE supplementation may have a beneficial action to reduce bacterial UTI in dogs.  
Prospective clinical trials, including normal dogs as well as “at risk” dogs, are needed to assess 
the full effect of CE supplementation on urinary tract health.   
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Chapter 4 - Effect of Storage Time and Temperature on Canine 
Urine Enzymes 
 Introduction 
Acute kidney injury (AKI) in dogs can occur secondary to administration of potentially 
nephrotoxic drugs (e.g., antibiotics, antifungals, chemotherapeutics, and NSAIDs) and has a high 
mortality rate.
101
  Even in cases with reversible renal lesions, hospital-acquired AKI often leads 
to more serious consequences than the underlying disease process that required the initial 
hospitalization.
101
  Early recognition of kidney injury is important since extensive injury can 
occur before changes in routine blood work are detected.  In addition, continued administration 
of nephrotoxic medication after initial kidney injury occurs can lead to more serious injury.  
Early detection of AKI may result in adjustment of therapy, including discontinuing potentially 
nephrotoxic therapeutics, or when that is not possible, dose adjustments (e.g., either increasing 
time between doses or dose reduction), or initiating supportive measures (e.g., fluid therapy). 
Measurement of enzyme activity in urine may aid diagnosis of early nephrotoxicant-induced 
AKI.  γ-glutamyl transpeptidase (GGT) and N-acetyl-β-D-glucosaminidase (NAG) are two of the 
more commonly measured canine urine enzymes.  GGT originates from the proximal tubule 
brush border and NAG is present in the proximal tubule lysosomes.
102
  Although both enzymes 
are also present in the plasma, they are too large to be freely filtered by the normal glomerular 
capillary wall.  Studies have shown that measurement of these enzymes in the urine facilitates 
detection of early renal tubular damage prior to changes in serum biochemical parameters and 
urine specific gravity.
103,104
  
After acquisition of a urine sample, enzymuria determination may be delayed for sample 
batching and shipping to an outsourced laboratory.  In addition, sometimes sequential tests may 
be performed on an individual and compared, for example, baseline urine samples may be saved 
and run with post-treatment urine samples collected at a later time.  Therefore, it is important to 
know how storage of urine samples affects enzyme activity.  
Previous studies of GGT stability in the urine of healthy human beings found no changes in 
enzyme activity after short term storage (24 h) at room temperature or at 4°C, but found only 
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partial preservation of enzyme activity in urine supernatant stored at – 70°C.105  Urine enzyme 
stability was not maintained even after a few days of freezing at – 20°C.105  A recent study 
evaluating urinary biomarkers in dogs with known hereditary renal disease assessed urine NAG 
stability and reported decreased enzyme activity in 2 of 4 urine samples stored at room 
temperature for 12-24 hours.
106  
In addition, there was increased urine enzyme activity in 2 of 4 
samples stored at 4°C.
106
  Freezing at – 20°C or – 80°C for up to one year did not affect urine 
NAG activity.
106
  To the authors’ knowledge there have been no previous studies evaluating the 
stability of GGT in canine urine.  The purpose of the present study was to determine how sample 
storage affects NAG and GGT activity in canine urine. 
 Materials and Methods 
 Samples  
Sixty-six canine urine samples submitted to the Clinical Pathology Laboratory at Kansas State 
University were initially included.  Samples were collected from clinical patients at the 
Veterinary Medical Teaching Hospital at Kansas State University that had a variety of medical or 
surgical disorders.  Additionally, samples were selected based on the hours of operation of 
Clinical Pathology Laboratory to ensure timely sample analysis.  A minimum urine sample 
volume of 10 ml was required. 
 Laboratory Methods 
A complete urinalysis, including physical appearance, specific gravity via refractometer, 
chemical assessment via dip-stick, and microscopic evaluation of the sediment was performed on 
each sample.  Samples were excluded (n=25) if the pH was ≥ 8, there were > 10 white blood 
cells/hpf, > 50 red blood cells/hpf, or bacteriuria or gross pigmenturia.  Analysis of NAG, GGT 
and creatinine was performed on a Cobas c501 chemistry analyzer (Roche Diagnostics).  NAG 
activity in the fresh urine supernatant was assessed by colorimetric assay (Roche Diagnostics) in 
which 3-Cresolsulfonphthaleinyl-N-acetyl-β-D-glucosaminide is hydrolyzed by NAG which 
results in the release of 3-cresolsulfonphthalein (also referred to as 3-cresol purple).  The amount 
of 3-cresol produced is measured by photometric analysis to determine the NAG activity in the 
sample.  GGT activity in urine supernatant was measured by a colorimetric assay (Roche 
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Diagnostics) in which GGT transfers the γ-glutamyl group of L-γ-glutamyl-3-carboxy-4-
nitroanilide to glycylglycine.  The GGT activity in the sample is proportional to the amount of 5-
amino-2-nitrobenzoate (measured photometrically) produced in the sample.  For this 
methodology for both NAG and GGT, the amount of enzyme activity is determined by 
measuring the amount of product produced (i.e., the amount of product produced is directly 
proportional to the concentration of active enzyme).  Creatinine concentrations
 
were determined 
using the Jaffe reaction in which creatinine reacts with picrate in an alkaline solution to produce 
a yellow-red complex
 
(Roche Diagnostics).  The creatinine concentration in the sample is 
directly proportional to the color intensity of the yellow-red complex produced.  In the first phase 
of the study aliquots of urine supernatant were refrigerated at 4°C for 5 days and frozen at -20°C 
for 5 and 30 days at which time enzyme activity was reassessed (n=41).  In a second phase of the 
study, additional time and temperature points were added to the previous time points to include a 
30 day refrigerated sample (4°C) and a 30 day frozen sample (-70°C).  Thirty-two urine samples 
were initially evaluated for the second phase and 10 samples were excluded based on the 
previously described exclusion criteria.  For time/temperature points included in both phases of 
the study, data were analyzed together (n=63).  For comparison of the additional time-
temperature points added in phase 2, data from samples from the second phase (n=22) were 
analyzed separately. 
 Statistical Analysis 
Data were analyzed (STATA 11.2) by ANOVA accounting for repeated measures on samples.  
Differences in enzyme activity following storage were compared with activity in day 0 (fresh) 
samples using the ANOVA associated regression coefficients.  The overall model effects of 
storage were assessed using the Greenhouse-Geisser epsilon adjustment for repeated measures.  
 Results 
In analysis of the data points in the first phase, creatinine concentrations remained stable at all 
time and temperature points (data not shown).  In the analysis of time and temperatures from the 
first phase, urine GGT activity was stable in samples refrigerated for 5 days but there were 
significant declines (P < 0.01) in GGT activity in urine samples frozen at -20°C for 5 and 30 
days (Table 4.1).  Similarly, urine NAG activity was stable in samples refrigerated for 5 days, 
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but there were significant declines (P < 0.01) in NAG activity in urine samples frozen at -20°C 
for 5 and 30 days (Table 4.1).  In the analysis of time-temperatures from the second phase, 
creatinine concentrations remained stable at all-time/temperature points (data not shown).  Urine 
GGT activity was stable in the second study in samples refrigerated for 5 and 30 days and frozen 
at -70°C for 30 days but there were significant declines (P < 0.01) in GGT activity in urine 
samples frozen at -20°C for both 5 and 30 days (Table 4.2).  Similarly, urine NAG activity was 
stable in samples refrigerated for 5 and 30 days and frozen at -70°C for 30 days, but there were 
significant declines (P < 0.01) in NAG activity in urine samples frozen at -20°C for 5 and 30 
days (Table 4.2).  To summarize the results from both studies, enzyme activities for both NAG 
and GGT were stable after 5 days and 30 days of refrigeration (4°C) and after 30 days at -70°C, 
however there were significant (P < 0.01) declines in GGT and NAG activities when urine 
supernatants were frozen for 5 and 30 days at -20°C.  
 
Table 4.1 Phase 1 & 2:  Storage of GGT and NAG at 5 days refrigeration, 5 and 30 days 
frozen (-20°C) 
Storage Temp GGT-Mean (se) NAG-Mean (se) 
Fresh 55.98 (9.75)
 a
 5.84 (1.24)
 a
 
5 days refrigeration 50.97 (6.20)
a
 4.62 (0.85)
 a
 
5 days frozen (-20°C) 10.35 (3.12)
 b
 4.28 (0.83)
 b
 
30 days frozen (-20°C) 4.87 (1.14)
 b
 4.35 (0.84)
 b
 
a,b-Results in column only compared to fresh measurement.  Values in columns with b 
superscripts are different from fresh (p < 0.05).  N = 63.  se-Standard Error 
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Table 4.2 Phase 2:  Storage of GGT and NAG at 5 and 30 days refrigeration, 5 and 30 days 
frozen (-20°C) and 30 days frozen (-70°C) 
Storage Temp GGT-Mean (se) NAG-Mean (se) 
Fresh 55.14 (15.66)
 a
 3.24 (0.64)
 a
 
5 days refrigeration 53.27 (15.03)
 a
 3.20 (0.70)
 a
 
30 days refrigeration 44.95 (13.22)
 a
 3.60 (0.81)
 a
 
5 days frozen (-20°C) 5.93 (1.89)
 b
 2.93 (0.66)
 b
 
30 days frozen (-20°C) 4.11 (2.08)
 b
 2.95 (0.67)
b
 
30 days frozen (-70°C) 44.48 (12.52)
 a
 3.16 (0.69)
a
 
a,b-Results in column only compared to fresh measurement.  Values in columns with b 
superscripts are different from fresh (p < 0.05). N = 22.  se-Standard Error 
 
 Discussion 
Use of spot urine samples and urine enzyme/creatinine ratios (vs. timed urine collections) 
facilitates monitoring enzymuria in the clinical setting and correlates with 24-hour urinary 
enzyme excretion.
107
  Previous studies have suggested that a 2-3 fold increase in urine GGT and 
NAG activity compared with baseline values is indicative of renal tubular cell damage.
104
  The 
present study suggests that time and temperature do not affect urine creatinine concentrations but 
that storage temperature does affect urine GGT and NAG activity. 
Previously published canine reference intervals for normal dogs for urine NAG/creatinine ratios 
(0.02 to 3.63 U/g) and for urine GGT/creatinine ratios (1.93 to 28.57 U/g) demonstrated wide 
variability.
108
  In the current study, we made no comparison to gender since all comparisons were 
made to individual samples.  However a study in age matched healthy beagle dogs found NAG 
activity to be double in males versus females.
109
  Another study that evaluated GGT and NAG in 
healthy dogs found that GGT did not differ between sexes, however again there was a significant 
difference between male and female dogs and urine NAG.
108
  Maddens et al found significant 
differences in mean NAG/creatinine ratio between healthy bitches (2.3 U/g) and dogs with 
pyometra (14.3 U/g).  However, significant overlap existed between the two groups (range 1.4-
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3.9 U/g in healthy bitches and 0.8-14.3 U/g in pyometra dogs).
110
  This variability and the wide 
reference intervals, underscores the importance of comparing pre and post-treatment urine 
enzyme activity from the same patient rather than comparing an individual post-treatment value 
with a published normal value. 
Exclusion criteria for the urine samples in this study were selected based on knowledge that 
certain conditions in the urine (pH ≥ 8, and the presence of gross pigmenturia, bacteria and/or 
pyuria) may affect accurate measurement of enzyme activity.  Under alkaline conditions (pH of 
about 8), Morita et al found that NAG isoenzyme A, which is the major measured enzyme in 
normal urine, can become inactivated.
111
  There were no changes in urine NAG activity when 
measured in acidic urine.
111
  Morita et al suggested usage of an assay evaluating isoenzyme B if 
measurement should be performed on alkaline urine.  Another study by Madnic et al found that a 
pH of 8 or greater was associated with significant decreases in total NAG activity.
112
  Madnic et 
al used an alternative method of analysis by determining urine NAG after ultrafiltration, dialysis, 
and chromatographic separation on DEAE cellulose to isolate separate isoenzymes for analysis 
for more accurate results.  Since these additional analytical techniques were not used in the 
present study, samples containing alkaline urine were excluded. 
Samples containing gross pigmenturia were also excluded.  The current study used a colorimetric 
assay to evaluate enzyme activity of both NAG and GGT.  Therefore any sample that contained 
pigmenturia could lead to inaccurate results.  In addition to pigmenturia, samples with hematuria 
(defined in this study as >50 rbc/hpf) were also excluded.  The intention of measuring NAG and 
GGT in urine is to determine if there is increased release of enzymes as a result of renal tubular 
epithelial cell injury.  However, since these enzymes are also present in the blood, any sample 
that contained hematuria was excluded. 
Samples that contained any bacteriuria or pyuria (pyuria was defined as > 10 wbc/hpf in this 
study) were also excluded.  A study evaluating NAG and GGT activity in clinically normal adult 
dogs, and with normal biochemical profile, found concentrations within reference intervals for 
patients with positive cultures (4/38 or 10% of the time).
108
  However, since the enzyme to 
creatinine ratio may be affected by the presence of pyuria or infection, samples containing 
bacteriuria or pyuria were excluded.
102,107 
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Our results are similar to previous reports of GGT measurements in people finding decreased 
activity of GGT freezing at -20° C, however enzyme activity was maintained at -70° C.
105
   
Since pH has been previously shown to affect enzymuria measurement, it is also possible that 
changes in pH could also affect protein stability.  In this study, no attempt was made to 
standardize or compare pH at different storage levels.  However, comparing pH between 
individual samples, or standardization of pH prior to storage could be considered for future 
studies.  It is also unclear if the same decrease in enzyme activity would occur if blood samples 
were analyzed, or if some other compound present in the urine contributes to the storage 
differences.  Based on the assay performed, we are unsure if the concentration of the enzyme or 
the activity of the enzyme is responsible for the decline in measured product.  Future studies 
evaluating the structure of the protein before and after storage in combination with measured 
results could provide more insight into reasons for the difference seen between freezing 
temperatures. 
 Conclusion 
Measurement of urine NAG and GGT activity may aid early detection of AKI.  To ensure 
accurate and precise results, it is important for the clinician to be aware of factors that affect 
urine enzyme activity measurement, including appropriate sample storage techniques.  The 
interpretation of urine enzyme activity should always include a complete urinalysis as well as a 
creatinine concentration for determination of the enzyme/creatinine ratio.  If possible, a baseline 
sample should be collected.  Refrigeration or freezing of the urine supernatant sample at -70°C 
can provide accurate and reliable results for up to 30 days.  The present study shows that urine 
GGT and NAG activity is decreased in urine supernatant frozen at -20°C. 
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